ÂÜÀòÂÒÂ×

David Bearss Ph.D. is currently holding multiple positions in various companies including Halia Therapeutics, Biolexis Therapeutics, Inc., BioUtah, UVB Capital, University of Utah, Canary Speech, Systems Oncology, and Reglagene. With a background in Oncology and Cancer Biology, David has also served on the board of directors, as a partner, president, and senior managing director in different organizations. David holds a Ph.D. in Cell and Molecular Biology and a B.S. in Human Biology.